Nik Sol
Overview
Explore the profile of Nik Sol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
963
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Lierop Z, Wessels M, Lekranty W, Moraal B, Hof S, Hogenboom L, et al.
Mult Scler
. 2024 Oct;
30(13):1620-1629.
PMID: 39420574
Background And Objectives: Serum neurofilament light (sNfL) is a biomarker for neuro-axonal damage in multiple sclerosis (MS). Clinical implementation remains limited. We investigated the impact of implementation on clinical decisions...
2.
Sol N, Kooi E, Pages-Gallego M, Brandsma D, Bugiani M, de Ridder J, et al.
Acta Neuropathol
. 2024 Sep;
148(1):35.
PMID: 39225924
No abstract available.
3.
van der Wel J, Boelens M, Jebbink M, Smulders S, Maas K, Luitse M, et al.
Neuro Oncol
. 2024 Aug;
26(12):2316-2327.
PMID: 39110039
Background: Diagnosis and treatment of leptomeningeal metastases (LM) in epidermal growth factor receptor mutation-positive (EGFRm +) non-small-cell lung carcinoma (NSCLC) is challenging. We aimed to identify resistance mechanisms (RM) to...
4.
Sol N, Hartman J, Ten Kate M, van Kempen Z, van der Kooi A, Vandertop P, et al.
Am J Emerg Med
. 2023 Dec;
76:272.e3-272.e5.
PMID: 38072732
Hirayama disease is a self-limiting cervical motor neuron disease, usually affecting the spinal cord at level C7-T1. We share an unusual case of Hirayama disease in a young man affecting...
5.
Antunes-Ferreira M, DAmbrosi S, Arkani M, Post E, In t Veld S, Ramaker J, et al.
Sci Rep
. 2023 Jun;
13(1):9359.
PMID: 37291189
Liquid biopsy approaches offer a promising technology for early and minimally invasive cancer detection. Tumor-educated platelets (TEPs) have emerged as a promising liquid biopsy biosource for the detection of various...
6.
Muller M, Best M, van der Noort V, Hiltermann T, Niemeijer A, Post E, et al.
Tumour Biol
. 2023 Jun;
46(s1):S327-S340.
PMID: 37270827
Background: Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment response prediction may improve patient allocation for...
7.
Gao Y, Liu C, Li H, Xiong X, Li G, In t Veld S, et al.
Protein Cell
. 2023 Mar;
14(6):579-590.
PMID: 36905391
Platelets are reprogrammed by cancer via a process called education, which favors cancer development. The transcriptional profile of tumor-educated platelets (TEPs) is skewed and therefore practicable for cancer detection. This...
8.
Post E, Sol N, Best M, Wurdinger T
Neurooncol Adv
. 2022 Nov;
4(Suppl 2):ii61-ii65.
PMID: 36380866
Blood-based liquid biopsies are an upcoming approach for earlier cancer detection, diagnostics, prognostics, therapy-response prediction, and therapy monitoring, including in patients with tumors of the central nervous system. Among these,...
9.
In t Veld S, Arkani M, Post E, Antunes-Ferreira M, DAmbrosi S, Vessies D, et al.
Cancer Cell
. 2022 Sep;
40(9):999-1009.e6.
PMID: 36055228
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for...
10.
Smits A, Arkani M, In t Veld S, Huis In t Veld A, Sol N, Groeneveldt J, et al.
Ann Am Thorac Soc
. 2022 May;
19(10):1650-1660.
PMID: 35537078
Pulmonary hypertension encompasses progressive disorders leading to right ventricular dysfunction and early death. Late detection is an important cause of poor clinical outcomes. However, biomarkers that accurately predict the presence...